Our Odyssey

The challenges facing young adults differ from those affecting older adults and are not always being heard or addressed. The burdens that young adults carry include coping with their disease, talking with family, friends, and romantic partners about their health condition, planning their future (family and career), and finding beneficial and responsible peer-support. The transition from childhood or adolescence to adulthood is often a time of uncertainty and the onset of complex emotions.

Founded in 2019, Our Odyssey is a 501(c)(3) nonprofit to address these unmet needs and provide year round in-person and virtual meetups to young adults between the ages of 18-35. Our Odyssey’s mission is to connect young adults impacted by a rare or chronic condition with social and emotional support in the hope of improving their quality of life. To learn more, please visit www.ourodyssey.org or contact us at [email protected].

Condition Awareness & Advocacy

Here is a list of conditions this partner raises awareness and advocacy for:

Resources & Support

Connect With Our Odyssey

Patient Worthy Posts on Chronic Illness

Povorcitinib, a potential treatment for prurigo nodularis, performed well in Phase 2 studies. This treatment is orally administered. In this photo, someone pours out a bottle of white pills into their hand.

Povorcitinib Performs Well in Phase 2 Prurigo Nodularis Study

Dupixent has long been known as a therapy which reduces itch, slows disease progression, and reduces exacerbations in a number of allergic conditions such as

Sodium Valproate Shows Efficacy in Treating Patchy Alopecia Areata

Corticosteroids are one of the standards-of-care for treating alopecia areata, alongside treatments such as topical sensitizers and Rogaine. However, none of these treatments have a

Alopecia areata causes patchy hair loss. In this photo, someone sits with their hand on their hair and holds up loose hair to the camera.

Fewer than 33% of People with Alopecia Areata Attend Support Groups

Having a chronic illness can be isolating. It can be difficult to share vulnerable and sensitive information about yourself with others, or to find ways

Dupixent Label Expands to Include Children Ages 1-11 with Eosinophilic Esophagitis

In late January 2024, the U.S. Food and Drug Administration approved a label expansion for Dupixent (dupilumab). Dupixent, a monoclonal antibody targeting IL-4 and IL-13,

Dupixent Label Update Reflects Safety and Efficacy Results for Moderate-to-Severe Atopic Dermatitis with Severe Hand/Foot Involvement

According to reporting from Healio Psoriatic Disease, the Food and Drug Administration (FDA) recently updated the label for Dupixent (dupilumab) in the indication of moderate-to-severe

Research Suggests That Maternal and Infant Antibiotic Exposure Heightens EoE Risk

Over the last three decades, researchers and doctors have noticed a concerning trend: increasing cases of eosinophilic esophagitis (EoE), a chronic digestive system disorder, in